Aequilibrium Pharma is a biotechnology company developing and commercialising high quality mabs.
The company is focused on creating a deep pipeline of clinically identical biosimilars at significantly reduced prices for entry into both new and established markets.
Our current pipeline consists of severals biosimilars and several monoclonal antibodies aimed at treating cancer, autoimmune, inflammatory and other diseases.
We develop, produce and release our APIs and biosimilars in house with the latest available technology and to the highest quality standards for the supply of finished and ready to commercialize products worldwide.
Aequlibrium pharma sign and agreement with one of the world’s premier provider of services related to preclinical development of biosimilars.
Aequilibrium Pharma is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases. Our core values are life-improvement, collaboration, innovation and novel therapy.